ENDRA Life Sciences (NASDAQ:NDRA) Shares Cross Below 200-Day Moving Average – Here’s What Happened

ENDRA Life Sciences Inc. (NASDAQ:NDRA)’s stock price crossed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $4.81 and traded as low as $4.70. ENDRA Life Sciences shares last traded at $4.7750, with a volume of 1,200 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, November 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $25.00.

ENDRA Life Sciences Stock Performance

The firm has a market cap of $7.16 million, a price-to-earnings ratio of -0.75 and a beta of -0.07. The business’s 50 day moving average price is $5.43 and its 200-day moving average price is $4.81.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.21. On average, analysts forecast that ENDRA Life Sciences Inc. will post -4.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in ENDRA Life Sciences stock. Citizens Financial Group Inc. RI purchased a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the second quarter, according to its most recent filing with the SEC. The fund purchased 28,400 shares of the company’s stock, valued at approximately $151,000. Citizens Financial Group Inc. RI owned about 2.24% of ENDRA Life Sciences at the end of the most recent quarter. Hedge funds and other institutional investors own 1.19% of the company’s stock.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company developing noninvasive diagnostic tools for tissue characterization. The company’s lead technology is Thermo-Acoustic Enhanced Ultrasound (TAEUS), which is designed to enhance conventional ultrasound systems with additional information about tissue properties.

ENDRA is initially applying TAEUS to the assessment of liver disease, including the detection and measurement of liver fat associated with conditions such as nonalcoholic fatty liver disease.